research use only
Cat.No.S8136
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease |
|---|---|
| Other Serine Protease Inhibitors | Leupeptin Hemisulfate PMSF Nafamostat mesilate (FUT-175) AEBSF HCl Gabexate Mesylate Alvelestat (AZD9668) Sivelestat sodium tetrahydrate UK-371804 HCl Fulacimstat ZK824859 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| BEAS2B | Function assay | 6 hrs | Inhibition of human neutrophil elastase-induced decrease in mICAM1 level expressed in BEAS2B cells assessed as cytoprotective activity after 6 hrs by Western blotting analysis | 23350733 | ||
| BEAS2B | Function assay | 6 hrs | Inhibition of human neutrophil elastase-induced increase in sICAM1 level in culture medium expressed in BEAS2B cells assessed as cytoprotective activity after 6 hrs | 23350733 | ||
| BEAS2B | Function assay | 100 uM | 12 hrs | Inhibition of human neutrophil elastase-induced desquamation expressed in BEAS2B cells assessed as cytoprotective activity at 100 uM after 12 hrs by trypan blue staining-based bright field microscopic analysis | 23350733 | |
| BEAS2B | Function assay | 100 uM | Inhibition of human neutrophil elastase-induced cell morphological changes expressed in BEAS2B cells assessed as cytoprotective activity at 100 uM incubated 12 to 24 hr by trypan blue staining-based bright field microscopic analysis | 23350733 | ||
| BEAS2B | Function assay | 3 hrs | Inhibition of human neutrophil elastase-induced cell morphological changes expressed in BEAS2B cells assessed as cytoprotective activity after 3 hrs by trypan blue staining-based bright field microscopic analysis | 23350733 | ||
| BEAS2B | Function assay | 100 uM | Inhibition of human neutrophil elastase-induced antiproliferative activity expressed in BEAS2B cells assessed as cytoprotectivity at 100 uM by MTT assay | 23350733 | ||
| Click to View More Cell Line Experimental Data | ||||||
| Molecular Weight | 434.46 | Formula | C20H22N2O7S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 127373-66-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | ONO-5046, LY544349, EI546 | Smiles | CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O | ||
|
In vitro |
DMSO
: 87 mg/mL
(200.24 mM)
Ethanol : 8 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
neutrophil elastase
|
|---|---|
| In vitro |
sivelestat reduces the levels of inflammatory mediators by inhibiting NF-kB. It suppresses the growth of gastric cancer cells by inhibiting the release of TGF-α stimulated by NE; Sivelestat suppresses iNOS gene expression in proinflammatory cytokine-stimulated hepatocytes.
|
| In vivo |
sivelestat could attenuate sepsis-related kidney injury in rats. It blocks GAPDH/Siah1 which is a novel signaling pathway during the progression of spinal cord injury. Administration of sivelestat attenuates pulmonary fibrosis after acute lung injury in mice.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.